- Home
- JG vs IMMX Comparison
JG vs IMMX Comparison
Compare JG & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JG
- IMMX
- Stock Information
- Founded
- JG 2012
- IMMX 2014
- Country
- JG China
- IMMX United States
- Employees
- JG N/A
- IMMX N/A
- Industry
- JG Computer Software: Programming Data Processing
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- JG Technology
- IMMX Health Care
- Exchange
- JG Nasdaq
- IMMX Nasdaq
- Market Cap
- JG 52.8M
- IMMX 50.1M
- IPO Year
- JG 2018
- IMMX 2021
- Fundamental
- Price
- JG $11.51
- IMMX $2.34
- Analyst Decision
- JG
- IMMX Strong Buy
- Analyst Count
- JG 0
- IMMX 1
- Target Price
- JG N/A
- IMMX $7.00
- AVG Volume (30 Days)
- JG 17.7K
- IMMX 360.1K
- Earning Date
- JG 05-29-2025
- IMMX 06-10-2025
- Dividend Yield
- JG N/A
- IMMX N/A
- EPS Growth
- JG N/A
- IMMX N/A
- EPS
- JG N/A
- IMMX N/A
- Revenue
- JG $46,938,193.00
- IMMX N/A
- Revenue This Year
- JG $10.90
- IMMX N/A
- Revenue Next Year
- JG N/A
- IMMX N/A
- P/E Ratio
- JG N/A
- IMMX N/A
- Revenue Growth
- JG 17.73
- IMMX N/A
- 52 Week Low
- JG $2.36
- IMMX $1.26
- 52 Week High
- JG $20.94
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- JG 67.64
- IMMX 61.49
- Support Level
- JG $10.90
- IMMX $1.89
- Resistance Level
- JG $9.72
- IMMX $2.50
- Average True Range (ATR)
- JG 0.55
- IMMX 0.17
- MACD
- JG 0.24
- IMMX 0.00
- Stochastic Oscillator
- JG 84.42
- IMMX 73.77
About JG Aurora Mobile Limited
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.